Lack of efficacy of quinapril on vascular damage in limited cutaneous systemic sclerosis

Nature Clinical Practice Rheumatology

Volumn 4, Issue 6, 2008, Pages 288-289

  Guiducci, Serena ^a   Cerinic, Marco Matucci ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; CARBON MONOXIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; PLACEBO; QUINAPRIL;

ARTICLE; BLOOD VESSEL INJURY; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EFFECT SIZE; FINGER BLOOD FLOW; FORCED EXPIRATORY VOLUME; FREQUENCY ANALYSIS; HEALTH STATUS; HUMAN; ISCHEMIA; LUNG ARTERY PRESSURE; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; MAXIMUM TOLERATED DOSE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUANTITATIVE STUDY; RAYNAUD PHENOMENON; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SHORT FORM 36; SKIN ULCER; SYSTEMIC SCLEROSIS;

EID: 44849104758     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0803     Document Type: Article

References (9)

1. Steen VD et al. (1990) Outcome of renal crisis in systemic sclerosis: Relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 113: 352-357
2. Challenor VF (1994) Angiotensin converting enzyme inhibitors in Raynaud's phenomenon. Drugs 48: 864-867
3. Aikimbaev KS et al. (1996) Comparative assessment of the effects of vasodilators on peripheral vascular reactivity in patients with systemic scleroderma and Raynaud's phenomenon: Color Doppler flow imaging study. Angiology 47: 475-480
4. Abraham MR et al. (2002) Angiotensin-converting enzyme genotype modulates pulmonary function and exercise capacity in treated patients with congestive stable heart failure. Circulation 106: 1794-1799
5. Lefebvre F et al. (2006) Modification of the pulmonary renin-angiotensin system and lung structural remodelling in congestive heart failure. Clin Sci (Lond) 111:217-224
6. Kuba K et al. (2006) Angiotensin-converting enzyme 2 in lung diseases. Curr Opin Pharmacol 6: 271-276
7. Ostrowski S et al. (1999) Enalapril (10mg/day) in systemic sclerosis. One year, double blind, randomised study (ESS-1): Pulmonary substudy-effects of three month treatment. Adv Exp Med Biol 455 289-293
8. Richard C et al. (1983) Value of captopril in the treatment of systemic arterial and pulmonary hypertension with increased plasma renin in scleroderma [French]. Rev Med Interne 4: 125-129
9. Alpert MA et al. (1992) Short- and long-term hemodynamic effects of captopril in patients with pulmonary hypertension and selected connective tissue disease. Chest 102: 1407-1412